Format

Send to

Choose Destination
J Control Release. 2016 Feb 10;223:215-223. doi: 10.1016/j.jconrel.2015.12.048. Epub 2015 Dec 28.

TRAIL-coated leukocytes that prevent the bloodborne metastasis of prostate cancer.

Author information

1
Meinig School of Biomedical Engineering, Cornell University, 526 N. Campus Rd, Weill Hall, Ithaca, NY 14853, United States.
2
Meinig School of Biomedical Engineering, Cornell University, 526 N. Campus Rd, Weill Hall, Ithaca, NY 14853, United States. Electronic address: mike.king@cornell.edu.

Abstract

Prostate cancer, once it has progressed from its local to metastatic form, is a disease with poor prognosis and limited treatment options. Here we demonstrate an approach using nanoscale liposomes conjugated with E-selectin adhesion protein and Apo2L/TRAIL (TNF-related apoptosis-inducing ligand) apoptosis ligand that attach to the surface of leukocytes and rapidly clear viable cancer cells from circulating blood in the living mouse. For the first time, it is shown that such an approach can be used to prevent the spontaneous formation and growth of metastatic tumors in an orthotopic xenograft model of prostate cancer, by greatly reducing the number of circulating tumor cells. We conclude that the use of circulating leukocytes as a carrier for the anti-cancer protein TRAIL could be an effective tool to directly target circulating tumor cells for the prevention of prostate cancer metastasis, and potentially other cancers that spread through the bloodstream.

KEYWORDS:

Circulating tumor cells; Metastasis; Nanomedicine; TRAIL

PMID:
26732555
PMCID:
PMC4724502
DOI:
10.1016/j.jconrel.2015.12.048
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center